Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
AALL1732
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT03959085 ↗
- Recruiting
- Children's Oncology Group
- Focused
We haven't built an HCP commentary report on AALL1732 (inotuzumab ozogamicin in high-risk B-ALL, mixed phenotype acute leukemia, B-LLy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AALL1732 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 1 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia; Mixed Phenotype Acute Leukemia; Testicular Leukemia
- Interventions
- Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Scan; Calaspargase Pegol; Computed Tomography; Cyclophosphamide; Cytarabine; Daunorubicin Hydrochloride; Dexamethasone; Doxorubicin Hydrochloride; Inotuzumab Ozogamicin; Leucovorin Calcium; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Pegaspargase; Positron Emission Tomography; Prednisolone; Prednisone; Questionnaire Administration; Radiation Therapy; Radiation Therapy; Thioguanine; Vincristine Sulfate
- Arms
- Arm D (CD 22 positive HR B-ALL) · Active comparator
- Arm E (CD22 positive HR B-ALL) · Experimental
- Arm I (MPAL) · Experimental
- Arm II (B-LLy) · Experimental
- Enrollment
- 5,951 (estimated)
- Primary outcomes
- Post-induction 5-year event-free survival (EFS)
- Sponsor
- Children's Oncology Group with National Cancer Institute (NCI)
- Start
- Oct 31, 2019
- Primary completion
- Mar 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT03959085 · updated Aug 25, 2026
Publications
linked from the registry- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463